Aladro Benito, YolandaTerrero, RodrigoCerezo García, MartaGinestal, RicardoAyuso, LucíaMeca Lallana, VirginiaMillán, JorgeBorrego, LauraMartínez Ginés, MarisaThuissard Vasallo, Israel JohnEt al.2019-11-072019-11-072016Aladro, Y., Terrero, R., Cerezo, M., Ginestal, R., Ayuso, L., Meca-Lallana, V., … Meca-Lallana, J. (2016). Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain. Journal of the Neurological Sciences, 365, 16–21. https://doi.org/10.1016/j.jns.2016.03.0500022-510Xhttp://hdl.handle.net/11268/8391Objective To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. Methods Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (± 0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. Results The overall anti-JCV seroprevalence was 55.3% (51.6–58.9), similar across regions (p = 0.073). It increased with age (p < 0.000) and when STRATIFY-2 was used (60.5%, p = 0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. Conclusions JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions.engAnti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spainjournal article10.1016/j.jns.2016.03.050restricted accessEsclerosis múltipleEnfermedades víricasEnfermedad del sistema nerviosoVirus